Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Associated Therapies: -

Clinical Trials

Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal

Phase 4

Completed

Conditions: Esophageal Varices
Portal Hypertension Gastropathy
Spontaneous Bacterial Peritonitis
Hepatic Encephalopathy
Ascites

Interventions: Drug: placebo
Drug: carvedilol
Drug: propranolol

First Posted Date: 2010-01-29

Last Posted Date: 2017-08-22

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 201

Registration Number: NCT01059396

Locations: 🇪🇸
Hospital Arnau de Vilanova, Lérida, Spain
🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
🇪🇸
Hospital German Trias i Pujol, Badalona, Spain

and more 5 locations

Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2009-08-25

Last Posted Date: 2017-06-08

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 10

Registration Number: NCT00964678

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.

Phase 4

Completed

Conditions: Hypoxia
Altitude
Heart Failure

Interventions: Drug: placebo
Drug: Carvedilol
Drug: Nebivolol

First Posted Date: 2009-06-19

Last Posted Date: 2009-09-02

Lead Sponsor: Istituto Auxologico Italiano

Target Recruit Count: 27

Registration Number: NCT00924833

Locations: 🇮🇹
Laboratorio Ricerche Cardiologiche. Istituto Auxologico Italiano. Ospedale S. Luca. Via Spagnoletto, 3. Regina Margherita Hut (Monte Rosa, Italian Alps, 4559 m), Milan, Italy

Mechanisms and Treatment of Intradialytic Hypertension

Phase 4

Completed

Conditions: Intradialytic Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2009-01-23

Last Posted Date: 2020-11-03

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 55

Registration Number: NCT00827775

Locations: 🇺🇸
UTS Dallas Dialysis (Elmbrook), Dallas, Texas, United States
🇺🇸
UTSW Oakcliff Davita Dialysis, Dallas, Texas, United States
🇺🇸
UTSW Dallas East Davita Dialysis (Buckner unit), Dallas, Texas, United States